Menkes Disease

The U.S. Food and Drug Administration has recently approved Zycubo (copper histidinate) as the first treatment for Menkes disease in pediatric patients. This marks a significant breakthrough in the management of this rare and life-threatening genetic disorder.

About Menkes Disease

Menkes disease is a rare genetic disorder that affects the body’s ability to absorb, transport, and regulate copper levels.

It is caused by a mutation in the ATP7A gene, which is located on the X chromosome. The ATP7A gene plays a crucial role in maintaining proper copper balance in the body. Because the disorder is X-linked, it occurs mostly in male infants.

Although the body requires only a small amount of copper, it is essential for several vital functions, including:

• Metabolism

• Brain development and functioning

• Formation of blood vessels and blood cells

• Wound healing

• Immune system functioning

• Conversion of iron into a usable form

Copper is naturally available in many foods and dietary supplements. However, in Menkes disease, the body cannot properly utilize it.

Pathophysiology

In Menkes disease:

• Copper levels are low in blood plasma, liver, and brain.

• The activity of copper-dependent enzymes is significantly reduced.

• Copper may accumulate in other tissues, such as the kidneys.

Because the body cannot use copper effectively, the disorder can lead to severe damage to the brain and nervous system, affecting overall growth and development.

Clinical Features

Menkes disease is sometimes referred to as “kinky hair disease” due to one of its most distinctive features.

Common Symptoms

• Coarse, brittle, kinky (crinkly) hair

• Seizures

• Slow growth and failure to thrive

• Floppy muscles (hypotonia)

• Developmental delays

The condition is estimated to occur in approximately 1 in 35,000 live male births.

Treatment

Currently, there is no complete cure for Menkes disease. However, early treatment with copper replacement therapy can help reduce symptoms and improve survival.

The newly approved drug Zycubo (copper histidinate) provides copper replacement injections, which help increase copper availability in the body and support enzyme activity.

Early intervention is crucial. Without treatment, most children with Menkes disease do not survive beyond the age of three years.

Significance of the Approval

The approval of Zycubo by the U.S. FDA is significant because:

• It provides the first officially approved treatment option for Menkes disease.

• It offers hope for improved survival and quality of life in affected children.

• It highlights advancements in rare disease management and pediatric genetic therapy.